Journal
CANCER AND METASTASIS REVIEWS
Volume 40, Issue 3, Pages 777-789Publisher
SPRINGER
DOI: 10.1007/s10555-021-09982-2
Keywords
Pancreatic cancer; Microbiome; Biomarker; Microbiota modulation
Categories
Funding
- National Cancer Institute [R01CA179243]
Ask authors/readers for more resources
Recent studies have revealed the significant impact of the microbiome on cancer development and treatment, especially in pancreatic ductal adenocarcinoma. Utilizing microbiome analyses can lead to the development of new diagnostic and therapeutic strategies, such as fecal microbiota transplantation, probiotics, and dietary changes.
Recent studies of the human microbiome have offered new insights into how the microbiome can impact cancer development and treatment. Specifically, in pancreatic ductal adenocarcinoma (PDAC), the microbiota has been shown to modulate PDAC risk, contribute to tumorigenesis, impact the tumor microenvironment, and alter treatment response. These findings provide rationale for further investigations into leveraging the microbiome to develop new strategies to diagnose and treat PDAC patients. There is growing evidence that microbiome analyses have the potential to become easily performed, non-invasive diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. More excitingly, there is now emerging interest in developing interventions based on the modulation of microbiota. Fecal microbiota transplantation, probiotics, dietary changes, and antibiotics are all potential strategies to augment the efficacy of current therapeutics and reduce toxicities. While there are still challenges to overcome, this is a rapidly growing field that holds promise for translation into clinical practice and provides a new approach to improving patient outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available